Literature DB >> 3642431

Comparison of four surfactants: in vitro surface properties and responses of preterm lambs to treatment at birth.

M Ikegami, Y Agata, T Elkady, M Hallman, D Berry, A Jobe.   

Abstract

Natural sheep surfactant, rabbit surfactant, human surfactant, and surfactant TA were compared for in vitro surface properties and for responses of preterm lambs to treatment. Equivalent amounts of sheep, rabbit, and human surfactants were needed to lower the surface tension to less than 10 dynes/cm, whereas four times less surfactant TA similarly lowered the surface tension. Surface-spreading rates were similar for the surfactants. The surface adsorption of the batch of human surfactant tested was much slower than was adsorption of the other surfactants. Ventilation was significantly improved in all surfactant-treated lambs relative to the control lambs, indicating the general efficacy of the surfactant treatments. Overall, surfactant TA had the best in vitro characteristics, yet the preterm lambs treated at birth with surfactant TA had lower PO2 values and higher ventilatory requirements than did the sheep surfactant-treated lambs. The in vivo responses to rabbit surfactant were intermediate between the responses to sheep surfactant and to surfactant TA. Human surfactant resulted in the least effective clinical response. More of the phosphatidylcholine associated with human surfactant and surfactant TA was lost from the alveoli and lung tissue after four hours of ventilation than was lost from sheep or rabbit surfactant-treated lambs. More intravascular radiolabeled albumin leaked into the alveoli of the surfactant TA-treated lambs than sheep or rabbit surfactant-treated lambs. The four surfactants also had different sensitivities to the effects on minimum surface tensions of the soluble proteins present in alveolar washes. The study demonstrates that the range of clinical responses was not predictable based on the in vitro surface properties that we measured.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3642431

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

1.  Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits.

Authors:  M Gupta; J M Hernandez-Juviel; A J Waring; F J Walther
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

2.  Response to bovine surfactant (surfactant TA) in two different HMD models (lambs and baboons).

Authors:  H Maeta; D Vidyasagar; T Raju; R Bhat; H Matsuda
Journal:  Eur J Pediatr       Date:  1988-02       Impact factor: 3.183

3.  Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.

Authors:  A E Pontiroli; E Pajetta; A Calderara; M Alberetto; G Pozza; V Manganelli; G Resmini; L Tessari; V Maresca
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

4.  Lung volume and pulmonary blood flow measurements following exogenous surfactant.

Authors:  J Alexander; A D Milner
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

5.  Fluorescence, polarized fluorescence, and Brewster angle microscopy of palmitic acid and lung surfactant protein B monolayers.

Authors:  M M Lipp; K Y Lee; A Waring; J A Zasadzinski
Journal:  Biophys J       Date:  1997-06       Impact factor: 4.033

Review 6.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

Review 7.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

8.  Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity.

Authors:  A van 't Veen; D Gommers; J W Mouton; J A Kluytmans; E J Krijt; B Lachmann
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

9.  In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function.

Authors:  B Lachmann; E P Eijking; K L So; D Gommers
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

10.  Vitamin K-dependent carboxylation of pulmonary surfactant-associated proteins.

Authors:  S R Rannels; K J Gallaher; R Wallin; D E Rannels
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.